Safety Concerns Put a Stop to Maternal RSV Vaccine Study

A vaccine given during pregnancy that prevents respiratory syncytial virus (RSV) in infants was about 66% effective at protecting against RSV-associated respiratory illness, and about 69% effective at protecting against severe disease, according to a study in the New England Journal of Medicine. The data came from a randomized clinical trial involving more than 5000 pregnant people and their infants in 24 countries.
Source: JAMA - Journal of the American Medical Association - Category: General Medicine Source Type: research